Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Can-Fite BioPharma ( (CANF) ) is now available.
On March 10, 2026, Can-Fite BioPharma held a Special General Meeting of Shareholders at which investors approved all three proposals that had been put to a vote, each receiving the required majority. The measures, originally outlined in a January 27, 2026 notice and proxy statement, mark the successful completion of the agenda for this special meeting and affirm shareholder support for the company’s proposed corporate actions.
The approval of all items on the ballot underscores alignment between management and shareholders at a time when Can-Fite continues to operate as a foreign private issuer under U.S. securities regulations. The meeting’s outcomes, formally recorded in a Form 6-K filed with the U.S. Securities and Exchange Commission, clear the way for the company to implement the approved proposals in its ongoing governance and operational plans.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an Israel-based biopharmaceutical company, listed in the United States as a foreign private issuer, that operates under the reporting framework for companies filing annual reports on Form 20-F. The company is headquartered on Ben Gurion Street in Ramat Gan, reflecting its primary operational base in the Israeli life sciences sector.
Average Trading Volume: 903,455
Technical Sentiment Signal: Sell
Current Market Cap: $8.93M
Learn more about CANF stock on TipRanks’ Stock Analysis page.